Featured Research

from universities, journals, and other organizations

Promising Treatment Target Found In Hodgkin Lymphoma

Date:
July 31, 2007
Source:
Dana-Farber Cancer Institute
Summary:
Scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells. Based on this finding, the researchers are now investigating targeted therapies to disable this molecular "bodyguard" and boost a patient's ability to fight the blood cancer.

Reed-Sternberg cells (seen here as dark brown cells)
Credit: Image courtesy of Dana-Farber Cancer Institute

Dana-Farber Cancer Institute scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells. Based on this finding, the researchers are now investigating targeted therapies to disable this molecular "bodyguard" and boost a patient's ability to fight the blood cancer.

If the strategy proves successful, patients might escape some of the long-term complications -- like heart damage and the threat of a second cancer -- caused by standard treatments that include radiation, said Margaret Shipp, MD, of Dana-Farber, who headed the study.

"We're excited about this treatment lead," said Shipp, a medical oncologist. "We are currently generating antibodies that can neutralize the 'bodyguard' protein, and we'd like to fast-track this experimental therapy into clinical trials."

Nearly 8,200 people in the United States -- the great majority of them young adults -- will be diagnosed with Hodgkin lymphoma in 2007, according to the American Cancer Society, with an estimated 1,070 deaths. The cancer begins in the lymph nodes and channels that distribute infection-fighting white blood cells around the body. Its symptoms can include swollen glands in the neck, night sweats and fatigue.

The biological trademark of Hodgkin lymphoma is a type of giant, mutant white blood cell called the Reed-Sternberg cell that is found in the lymph node tumors. While most solid cancers consist almost entirely of tumor cells, says Shipp, Hodgkin tumors, which can reach the size of a basketball, contain only about 5 percent cancerous Reed-Sternberg cells; the rest are different types of immune cells recruited to fight the tumor, but they are ineffective.

"You would expect with all these host immune cells attracted to the area of the tumor cells that they would mount a great antitumor response," Shipp says. "But that's not the case. There are a lot of immune cells, but they're the wrong kind."

The immune army includes different types of T cells, such as T helper 1 (Th1) cells designed to recognize and kill foreign infectious agents and sometimes tumors, T helper 2 (Th2) cells, which normally control allergic responses, and T regulatory (Treg) cells that suppress other T-cell types and shut down an immune response when the job is done. The Hodgkin tumors are overloaded with Th2 and Treg cells that act as bodyguards for the cancer by weakening the Th1 immune response against it.

Przemyslaw Juszczynski, MD, PhD, Jing Ouyang, PhD, and colleagues from the Shipp laboratory, together with collaborators from Brigham and Women's Hospital, the Broad Institute and the University of Buenos Aires, hunted for the source of the cancer cells' protection. Using gene microarray chips, the scientists looked for genes that were active in Reed-Sternberg cells but not in cells of another non-Hodgkin B-cell lymphoma.

The comparison revealed that a gene called Gal1 was up to 30 times more active in the Reed-Sternberg cells, causing them to secrete large quantities of a protein -- Gal1 or Galectin 1 -- that turns down the Th1 immune response. The Shipp team then defined the mechanism for Gal1 overexpression in Hodgkin lymphoma. Next, they demonstrated that Th1 immune cells underwent apoptosis, or cell death, when treated with Gal1, leaving increased numbers of Th2 cells and the suppressive Treg cells. Using a gene-silencing technique, RNA interference or RNAi, they then turned off the Gal1 gene in Hodgkin Reed-Sternberg cells and showed that it blocked the death of infiltrating normal Th1 cells, making them an equal force to the Th2 cells.

"Likely what's happening here is that the tumor cells essentially hijack a normal regulatory program and use it to avoid being knocked off by the immune response," explains Shipp, who is also a professor of medicine at Harvard Medical School. "These observations provide an important explanation for why you have this ineffective immune response in Hodgkin lymphoma."

She adds that this bodyguard strategy may not be limited to Hodgkin lymphoma. One of the collaborating authors, Gabriel Rabinovich, PhD, of the University of Buenos Aires, has blocked Gal1 in mice with a form of the deadly skin cancer melanoma, and the animal's immune system succeeded in eliminating the cancer, Shipp says. "We think it's very possible that this strategy will be applicable to other types of cancer."

A report will be posted online by the Proceedings of the National Academy of Sciences on July 30 and will appear in an upcoming print issue of the journal.

The study's other authors are Stefano Monti, PhD, Scott Rodig, MD, PhD, Kunihiko Takeyama, MD, PhD, Jeremy Abramson, MD, Wen Chen, PhD, and Jeffery Kutok, MD, PhD.

The research was funded by the Miller Family Research Foundation.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "Promising Treatment Target Found In Hodgkin Lymphoma." ScienceDaily. ScienceDaily, 31 July 2007. <www.sciencedaily.com/releases/2007/07/070730173454.htm>.
Dana-Farber Cancer Institute. (2007, July 31). Promising Treatment Target Found In Hodgkin Lymphoma. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2007/07/070730173454.htm
Dana-Farber Cancer Institute. "Promising Treatment Target Found In Hodgkin Lymphoma." ScienceDaily. www.sciencedaily.com/releases/2007/07/070730173454.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins